News & Media

Skylit Medical Changes Name to Clarify Medical, Appoints New CEO

San Diego medtech startup Skylit Medical has changed its name to Clarify Medical and brought in local executive James M. Sweeney as its new CEO. Sweeney is taking the reins from Martyn Gross, the company’s founder and CEO for the past two years. Gross, 33, will stay on as the company’s VP of innovation. “Martyn….

San Diego Business Journal

Press Releases

Research

Narrowband ultraviolet B (NBUVB) phototherapy in children with moderate to severe eczema: a comparative cohort study.

Darne S, Leech SN, Taylor AEM.
Br J Dermatol. 2014;170(1):150-6.

Atopic dermatitis can usually be controlled with appropriate skin care and topical steroids or topical calcineurin inhibitors. However, more severe disease can disrupt the life of a child and his or her family. All too often, parents receive repeated courses of systemic steroids, which can cause HPA axis suppression and growth retardation. Systemic immunosuppressives also….

Management of atopic dermatitis: safety and efficacy of phototherapy

Patrizi A, Raone B, Ravaiolo GM.
Clin Cosmet Investig Dermatol. 2015;8:511-520.

Atopic dermatitis (AD) is a common chronic inflammatory skin disease that can affect all age groups. Phototherapy represents a valid second-line intervention in those cases where non-pharmacological and topical measures have failed. This review illustrates the main trials comparing the efficacy and safety of the different forms of phototherapy. Clinicians mainly refer to the indications….

Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents

Sidbury R, Davis DM, Cohen DE, et al.
J Am Acad Dermatol 2014;71:327-49.

Atopic dermatitis is a chronic, pruritic inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in atopic dermatitis management and care, providing recommendations based on the available evidence. In this third of 4 sections, treatment of atopic dermatitis with phototherapy and….

Twenty-year follow-up using a postal survey of childhood vitiligo treated with narrowband ultraviolet-B phototherapy.

Lommerts JE, Njoo MD, de Rie MA, et al.
Br J Dermatol. 2017 Jan 24.

Vitiligo is a depigmenting skin disorder with an estimated prevalence of 1%. Childhood-onset vitiligo occurs in approximately a third of all cases. Early-onset childhood vitiligo tends to be a more extensive and progressive type of vitiligo. Narrowband ultraviolet-B (NB-UVB) phototherapy is an effective treatment option in active vitiligo and leads to >75% repigmentation in 14-75%….

Randomized, parallel group trial comparing home-based phototherapy with institution-based 308 excimer lamp for the treatment of focal vitiligo vulgaris.

Guan STT, Theng C, Chang A.
J Am Acad Dermatol. 2015;27(4):733-735.

While phototherapy is a treatment of choice for vitiligo, it is time consuming and generally carried out in a health institution. This study compared home-based phototherapy with institution-based excimer. The home based phototherapy group had better efficacy with 72% and 50% in the group achieving good and excellent repigmentation, respectively, in contrast to only 54%….

The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo.

Mohammad TF, Al-Jamal M, Hamzavi IH, et al.
J Am Acad Dermatol. 2017;76(5):879-888.

Narrowband ultraviolet B light (NBUVB) is an important component of the standard of care in vitiligo treatment. However, there are no consistent guidelines regarding the dosing and administration of NBUVB in vitiligo. In this study, experts in vitiligo treatment make broad recommendations to assist dermatologists in the treatment of vitiligo with NBUVB phototherapy.

Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability.

Farahnik B, Patel V, Beroukhim K, et al.
Psoriasis Targets and Therapy. 2016;6:105-111.

The efficacy and safety of biologic and phototherapy in treating moderate-to-severe psoriasis is well known. However, some patients may not respond well to biologic agents or phototherapy on their own and may require combination therapy. Skillfully combining a biologic agent and phototherapy may provide an additive improvement without much increase in risks. This study summarizes….

Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy.

Hearn RM, Kerr AC, Rahim KF, et al.
Br J Dermatol. 2008;159:931-5.

Narrow-band ultraviolet B (NB-UVB) phototherapy is a widely used treatment. Psoralen-UVA photochemotherapy (PUVA) increases skin cancer risk and some animal studies have raised the possibility of an increased risk with NB-UVB. This study assessed the effect of NB-UVB exposure treatment numbers on the risk of developing skin cancer. No significant association between NB-UVB treatment and….

Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.

Menter A, Korman NJ, Elmets CA, et al.
J Am Acad Dermatol. 2010;62:114-35.

Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this fifth of 6 sections of the guidelines of care for psoriasis, we discuss the use of ultraviolet (UV) light therapy for the treatment of patients with psoriasis. Treatment should be tailored to meet….